BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma

Daiichi Sankyo and AstraZeneca’s ENHERTU Recommended for EU Approval for HER2 Low and HER2 Ultralow Metastatic Breast Cancer

Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in th...

March 03, 2025 | News

WuXi Biologics Passes Japan’s PMDA GMP Inspection for Wuxi Drug Substance Facilities

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has...

February 28, 2025 | News

Thermo Fisher Scientific to Acquire Solventum’s Purification & Filtration Business for $4.1 Billion in Cash

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that the company has en...

February 25, 2025 | News

South Korea’s Celltrion Secures EU Approval for Three Biosimilar Products, Expanding Its Portfolio to 11 by 2025

Celltrion gains simultaneous regulatory approval of two monoclonal antibody biosimilars across three treatments – Eydenzelt® (aflibe...

February 19, 2025 | News

Pfizer and Astellas Announce Sustained Survival Benefit in Advanced Urothelial Cancer with PADCEV® and KEYTRUDA® Combination

Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination a...

February 11, 2025 | News

Henlius and Dr. Reddy’s Forge Licensing Deal for Daratumumab Biosimilar in U.S. and Europe

Shanghai Henlius Biotech, Inc. announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Redd...

February 07, 2025 | News

China Approves Sarclisa as First Anti-CD38 Therapy for Newly Diagnosed Multiple Myeloma Patients

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant A...

January 31, 2025 | News

Heather Hargett on How Merck’s HUB Organoids Acquisition is Reshaping 3D Cell Culture and Drug Development

In an exclusive interview with BioPharma APAC, Heather Hargett, Head of Cell Biology Reagents & Tools at MilliporeSigma ( Merck KGaA, Darmstadt, German...

January 10, 2025 | News

Zuellig Pharma Acquires Propan to Strengthen Consumer Health Portfolio in the Philippines

Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that it has completed the acquisition of Propan, a market leading brand in th...

January 07, 2025 | News

I-Mab Prioritizes Lead Program Givastomig to Advance Precision Immuno-Oncology for Gastric Cancer

Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritization ...

January 07, 2025 | News

Norgine Submits Marketing Authorisation Application to EMA for Eflornithine in High-Risk Neuroblastoma

Norgine announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk ne...

January 07, 2025 | News

Driving Precision Medicine with AI: Tomasz Jetka, PhD, on Ardigen’s Vision for 2025

In an exclusive conversation with BioPharma APAC, Tomasz Jetka, PhD, Director of AI at Ardigen, delves into the company's ambitious plans to revolutionize ...

December 16, 2024 | Interview

Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness

In an exclusive interview with BioPharma APAC, Mr. Brendan O’Callaghan, Executive Vice President, Manufacturing & Supply at Sanofi, sheds light o...

December 09, 2024 | News

Sanofi Introduces Asia's First Modulus Facility in Singapore, Redefining Biopharma Manufacturing

The facility’s novel concept shortens production timelines and enables rapid changes in production capacities across medicines B...

November 28, 2024 | News

Stay Connected